Oncofid-P-B

Phase 3Small molecule

FFidia Farmaceutici s.p.a.

Oncofid-P-B is one of 49 small molecule programs targeting Urinary Bladder Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary Bladder CancerActive, not recruiting

Urinary Bladder CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Urinary Bladder Cancer

#DrugCompanyPhaseTrials

Trexall

Xtandi

Taxol

Eloxatin

Pemazyre

Keflex

Entereg

Gemzar

Afinitor

Adriamycin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Active, not recruiting

Urinary Bladder Cancer

NCT05024773

Clinical

Trials by Indication[1]

Hyaluronic Acid1 trial

Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)

Completed·FFidia Farmaceutici s.p.a.·Phase 1·NCT04798703·20 enrolled

Non-muscle Invasive1 trial

ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.

Completed·FFidia Farmaceutici s.p.a.·Phase 2·NCT04661826·60 enrolled

Urinary Bladder Cancer1 trial

A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC)

Active, not recruiting·FFidia Farmaceutici s.p.a.·Phase 3·NCT05024773·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Oncofid-P-B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oncofid-P-B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oncofid-P-B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fidia Farmaceutici s.p.a. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFidia Farmaceutici s.p.a.

Oncofid-P-B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Hyaluronic Acid1 trial

Non-muscle Invasive1 trial

Urinary Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News